English
简体中文
Total: £ 56.28
Published Date: 2025-06-17 | Pages: 147 | Tables: 150 | Medical Care
In 2024, the global market size of Viral Vectors and Plasmid DNA Manufacturing was estimated to be worth US$ 844 million and is forecast to reach approximately US$ 2649 million by 2031 with a CAGR of 18.0% during the forecast period 2025-2031.
The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.
Global Viral Vectors and Plasmid DNA Manufacturing key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific, and Europe, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections , etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Viral Vectors and Plasmid DNA Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors and Plasmid DNA Manufacturing.
The Viral Vectors and Plasmid DNA Manufacturing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Viral Vectors and Plasmid DNA Manufacturing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vectors and Plasmid DNA Manufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
BioReliance
Cobra Biologics
Oxford BioMedica
UniQure
FinVector
MolMed
MassBiologics
Richter-Helm
FUJIFILM Diosynth Biotechnologies
Lonza
Aldevron
Eurogentec
Cell and Gene Therapy Catapult
Biovian
Thermo Fisher Scientific (Brammer Bio)
VGXI
PlasmidFactory
Segment by Type
Plasmid DNA
Viral Vectors
Segment by Application
Cancers
Inherited Disorders
Viral Infections
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Viral Vectors and Plasmid DNA Manufacturing in global and regional level.
Chapter 3: Detailed analysis of Viral Vectors and Plasmid DNA Manufacturing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Viral Vectors and Plasmid DNA Manufacturing revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Viral Vectors and Plasmid DNA Manufacturing Product Introduction
1.2 Market by Type
1.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Plasmid DNA
1.2.3 Viral Vectors
1.3 Market by Application
1.3.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Cancers
1.3.3 Inherited Disorders
1.3.4 Viral Infections
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Size Estimates and Forecasts
2.2 Viral Vectors and Plasmid DNA Manufacturing Market Size by Region: 2024 Versus 2031
2.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Revenue by Region: 2020-2025
2.2.2 Global Viral Vectors and Plasmid DNA Manufacturing Revenue Forecast by Region (2026-2031)
2.2.3 Global Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Viral Vectors and Plasmid DNA Manufacturing Revenue by Type (2020-2031)
3.1.2 Global Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Revenue by Application (2020-2031)
3.2.2 Global Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Plasmid DNA of Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Application
3.3.2 Viral Vectors of Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Application
4 Global Viral Vectors and Plasmid DNA Manufacturing by Company
4.1 Global Viral Vectors and Plasmid DNA Manufacturing Revenue by Company (2020-2025)
4.2 Global Viral Vectors and Plasmid DNA Manufacturing Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Viral Vectors and Plasmid DNA Manufacturing Companies around the World: Ranking by Revenue
4.3.2 Global Viral Vectors and Plasmid DNA Manufacturing Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Viral Vectors and Plasmid DNA Manufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Viral Vectors and Plasmid DNA Manufacturing Companies Headquarters & Product Type
4.4.1 Global Viral Vectors and Plasmid DNA Manufacturing Companies Headquarters
4.4.2 Date of International Companies Enter into Viral Vectors and Plasmid DNA Manufacturing Market
4.4.3 Global Viral Vectors and Plasmid DNA Manufacturing Companies Product & Service
4.4.4 Plasmid DNA Revenue Market Share of Viral Vectors and Plasmid DNA Manufacturing by Company
4.4.5 Viral Vectors Revenue Market Share of Viral Vectors and Plasmid DNA Manufacturing by Company
4.5 Global Viral Vectors and Plasmid DNA Manufacturing Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 BioReliance
5.1.1 BioReliance Corporation Information
5.1.2 BioReliance Description, Business Overview
5.1.3 BioReliance Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.1.4 BioReliance Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.1.5 BioReliance Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.1.6 BioReliance Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.1.7 BioReliance Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.1.8 BioReliance Recent Developments
5.2 Cobra Biologics
5.2.1 Cobra Biologics Corporation Information
5.2.2 Cobra Biologics Description, Business Overview
5.2.3 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.2.4 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.2.5 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.2.6 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.2.7 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.2.8 Cobra Biologics Recent Developments
5.3 Oxford BioMedica
5.3.1 Oxford BioMedica Corporation Information
5.3.2 Oxford BioMedica Description, Business Overview
5.3.3 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.3.4 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.3.5 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.3.6 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.3.7 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.3.8 Oxford BioMedica Recent Developments
5.4 UniQure
5.4.1 UniQure Corporation Information
5.4.2 UniQure Description, Business Overview
5.4.3 UniQure Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.4.4 UniQure Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.4.5 UniQure Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.4.6 UniQure Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.4.7 UniQure Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.4.8 UniQure Recent Developments
5.5 FinVector
5.5.1 FinVector Corporation Information
5.5.2 FinVector Description, Business Overview
5.5.3 FinVector Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.5.4 FinVector Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.5.5 FinVector Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.5.6 FinVector Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.5.7 FinVector Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.5.8 FinVector Recent Developments
5.6 MolMed
5.6.1 MolMed Corporation Information
5.6.2 MolMed Description, Business Overview
5.6.3 MolMed Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.6.4 MolMed Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.6.5 MolMed Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.6.6 MolMed Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.6.7 MolMed Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.6.8 MolMed Recent Developments
5.7 MassBiologics
5.7.1 MassBiologics Corporation Information
5.7.2 MassBiologics Description, Business Overview
5.7.3 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.7.4 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.7.5 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.7.6 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.7.7 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.7.8 MassBiologics Recent Developments
5.8 Richter-Helm
5.8.1 Richter-Helm Corporation Information
5.8.2 Richter-Helm Description, Business Overview
5.8.3 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.8.4 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.8.5 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.8.6 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.8.7 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.8.8 Richter-Helm Recent Developments
5.9 FUJIFILM Diosynth Biotechnologies
5.9.1 FUJIFILM Diosynth Biotechnologies Corporation Information
5.9.2 FUJIFILM Diosynth Biotechnologies Description, Business Overview
5.9.3 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.9.4 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.9.5 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.9.6 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.9.7 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.9.8 FUJIFILM Diosynth Biotechnologies Recent Developments
5.10 Lonza
5.10.1 Lonza Corporation Information
5.10.2 Lonza Description, Business Overview
5.10.3 Lonza Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.10.4 Lonza Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.10.5 Lonza Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.10.6 Lonza Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.10.7 Lonza Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.10.8 Lonza Recent Developments
5.11 Aldevron
5.11.1 Aldevron Corporation Information
5.11.2 Aldevron Description, Business Overview
5.11.3 Aldevron Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.11.4 Aldevron Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.11.5 Aldevron Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.11.6 Aldevron Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.11.7 Aldevron Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.11.8 Aldevron Recent Developments
5.12 Eurogentec
5.12.1 Eurogentec Corporation Information
5.12.2 Eurogentec Description, Business Overview
5.12.3 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.12.4 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.12.5 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.12.6 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.12.7 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.12.8 Eurogentec Recent Developments
5.13 Cell and Gene Therapy Catapult
5.13.1 Cell and Gene Therapy Catapult Corporation Information
5.13.2 Cell and Gene Therapy Catapult Description, Business Overview
5.13.3 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.13.4 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.13.5 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.13.6 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.13.7 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.13.8 Cell and Gene Therapy Catapult Recent Developments
5.14 Biovian
5.14.1 Biovian Corporation Information
5.14.2 Biovian Description, Business Overview
5.14.3 Biovian Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.14.4 Biovian Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.14.5 Biovian Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.14.6 Biovian Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.14.7 Biovian Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.14.8 Biovian Recent Developments
5.15 Thermo Fisher Scientific (Brammer Bio)
5.15.1 Thermo Fisher Scientific (Brammer Bio) Corporation Information
5.15.2 Thermo Fisher Scientific (Brammer Bio) Description, Business Overview
5.15.3 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.15.4 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.15.5 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.15.6 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.15.7 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.15.8 Thermo Fisher Scientific (Brammer Bio) Recent Developments
5.16 VGXI
5.16.1 VGXI Corporation Information
5.16.2 VGXI Description, Business Overview
5.16.3 VGXI Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.16.4 VGXI Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.16.5 VGXI Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.16.6 VGXI Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.16.7 VGXI Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.16.8 VGXI Recent Developments
5.17 PlasmidFactory
5.17.1 PlasmidFactory Corporation Information
5.17.2 PlasmidFactory Description, Business Overview
5.17.3 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Products Offered
5.17.4 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2020-2025)
5.17.5 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Revenue by Product in 2024
5.17.6 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Revenue by Application in 2024
5.17.7 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Revenue by Geographic Area in 2024
5.17.8 PlasmidFactory Recent Developments
6 North America
6.1 North America Viral Vectors and Plasmid DNA Manufacturing Market Size YoY Growth 2020-2031
6.2 North America Viral Vectors and Plasmid DNA Manufacturing Market Facts & Figures by Country (2020-2031)
6.3 North America Viral Vectors and Plasmid DNA Manufacturing Revenue by Type (2020-2025)
6.4 North America Viral Vectors and Plasmid DNA Manufacturing Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Revenue by Type (2020-2025)
7.4 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Revenue by Application (2020-2025)
8 Europe
8.1 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size YoY Growth 2020-2031
8.2 Europe Viral Vectors and Plasmid DNA Manufacturing Market Facts & Figures by Country (2020-2031)
8.3 Europe Viral Vectors and Plasmid DNA Manufacturing Revenue by Type (2020-2025)
8.4 Europe Viral Vectors and Plasmid DNA Manufacturing Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size YoY Growth 2020-2031
9.2 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Facts & Figures by Country (2020-2031)
9.3 Latin America Viral Vectors and Plasmid DNA Manufacturing Revenue by Type (2020-2025)
9.4 Latin America Viral Vectors and Plasmid DNA Manufacturing Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Revenue by Type (2020-2025)
10.4 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Viral Vectors and Plasmid DNA Manufacturing Supply Chain Analysis
11.2 Viral Vectors and Plasmid DNA Manufacturing Key Raw Materials and Upstream Suppliers
11.3 Viral Vectors and Plasmid DNA Manufacturing Clients Analysis
11.4 Viral Vectors and Plasmid DNA Manufacturing Sales Channel and Sales Model Analysis
11.4.1 Viral Vectors and Plasmid DNA Manufacturing Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Viral Vectors and Plasmid DNA Manufacturing Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Viral Vectors and Plasmid DNA Manufacturing Distributors
12 Viral Vectors and Plasmid DNA Manufacturing Market Dynamics
12.1 Viral Vectors and Plasmid DNA Manufacturing Industry Trends
12.2 Viral Vectors and Plasmid DNA Manufacturing Market Drivers
12.3 Viral Vectors and Plasmid DNA Manufacturing Market Challenges
12.4 Viral Vectors and Plasmid DNA Manufacturing Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Viral Vectors and Plasmid DNA Manufacturing Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Viral Vectors and Plasmid DNA Manufacturing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Viral Vectors and Plasmid DNA Manufacturing Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Viral Vectors and Plasmid DNA Manufacturing Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Viral Vectors and Plasmid DNA Manufacturing Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Viral Vectors and Plasmid DNA Manufacturing Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Viral Vectors and Plasmid DNA Manufacturing Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Viral Vectors and Plasmid DNA Manufacturing Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Viral Vectors and Plasmid DNA Manufacturing Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Viral Vectors and Plasmid DNA Manufacturing Revenue by Company (2020-2025) & (US$ Million)
Table 11. Viral Vectors and Plasmid DNA Manufacturing Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Viral Vectors and Plasmid DNA Manufacturing Players by Revenue (US$ Million) in 2024
Table 13. Global Viral Vectors and Plasmid DNA Manufacturing Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Viral Vectors and Plasmid DNA Manufacturing by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vectors and Plasmid DNA Manufacturing as of 2024)
Table 15. Global Viral Vectors and Plasmid DNA Manufacturing Companies Headquarters
Table 16. Date of International Companies Enter into Viral Vectors and Plasmid DNA Manufacturing Market
Table 17. Global Viral Vectors and Plasmid DNA Manufacturing Companies Product & Service
Table 18. Global Viral Vectors and Plasmid DNA Manufacturing Mergers & Acquisitions, Expansion Plans
Table 19. BioReliance Corporation Information
Table 20. BioReliance Description and Business Overview
Table 21. BioReliance Viral Vectors and Plasmid DNA Manufacturing Product
Table 22. BioReliance Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. BioReliance Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 24. BioReliance Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 25. BioReliance Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 26. BioReliance Recent Developments
Table 27. Cobra Biologics Corporation Information
Table 28. Cobra Biologics Description and Business Overview
Table 29. Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Product
Table 30. Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Cobra Biologics Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 32. Cobra Biologics Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 33. Cobra Biologics Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 34. Cobra Biologics Recent Developments
Table 35. Oxford BioMedica Corporation Information
Table 36. Oxford BioMedica Description and Business Overview
Table 37. Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Product
Table 38. Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Oxford BioMedica Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 40. Oxford BioMedica Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 41. Oxford BioMedica Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 42. Oxford BioMedica Recent Developments
Table 43. UniQure Corporation Information
Table 44. UniQure Description and Business Overview
Table 45. UniQure Viral Vectors and Plasmid DNA Manufacturing Product
Table 46. UniQure Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. UniQure Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 48. UniQure Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 49. UniQure Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 50. UniQure Recent Developments
Table 51. FinVector Corporation Information
Table 52. FinVector Description and Business Overview
Table 53. FinVector Viral Vectors and Plasmid DNA Manufacturing Product
Table 54. FinVector Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. FinVector Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 56. FinVector Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 57. FinVector Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 58. FinVector Recent Developments
Table 59. MolMed Corporation Information
Table 60. MolMed Description and Business Overview
Table 61. MolMed Viral Vectors and Plasmid DNA Manufacturing Product
Table 62. MolMed Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. MolMed Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 64. MolMed Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 65. MolMed Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 66. MolMed Recent Developments
Table 67. MassBiologics Corporation Information
Table 68. MassBiologics Description and Business Overview
Table 69. MassBiologics Viral Vectors and Plasmid DNA Manufacturing Product
Table 70. MassBiologics Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. MassBiologics Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 72. MassBiologics Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 73. MassBiologics Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 74. MassBiologics Recent Developments
Table 75. Richter-Helm Corporation Information
Table 76. Richter-Helm Description and Business Overview
Table 77. Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Product
Table 78. Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. Richter-Helm Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 80. Richter-Helm Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 81. Richter-Helm Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 82. Richter-Helm Recent Developments
Table 83. FUJIFILM Diosynth Biotechnologies Corporation Information
Table 84. FUJIFILM Diosynth Biotechnologies Description and Business Overview
Table 85. FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Product
Table 86. FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. FUJIFILM Diosynth Biotechnologies Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 88. FUJIFILM Diosynth Biotechnologies Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 89. FUJIFILM Diosynth Biotechnologies Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 90. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 91. Lonza Corporation Information
Table 92. Lonza Description and Business Overview
Table 93. Lonza Viral Vectors and Plasmid DNA Manufacturing Product
Table 94. Lonza Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. Lonza Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 96. Lonza Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 97. Lonza Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 98. Lonza Recent Developments
Table 99. Aldevron Corporation Information
Table 100. Aldevron Description and Business Overview
Table 101. Aldevron Viral Vectors and Plasmid DNA Manufacturing Product
Table 102. Aldevron Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Aldevron Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 104. Aldevron Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 105. Aldevron Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 106. Aldevron Recent Developments
Table 107. Eurogentec Corporation Information
Table 108. Eurogentec Description and Business Overview
Table 109. Eurogentec Viral Vectors and Plasmid DNA Manufacturing Product
Table 110. Eurogentec Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 111. Eurogentec Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 112. Eurogentec Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 113. Eurogentec Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 114. Eurogentec Recent Developments
Table 115. Cell and Gene Therapy Catapult Corporation Information
Table 116. Cell and Gene Therapy Catapult Description and Business Overview
Table 117. Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Product
Table 118. Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 119. Cell and Gene Therapy Catapult Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 120. Cell and Gene Therapy Catapult Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 121. Cell and Gene Therapy Catapult Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 122. Cell and Gene Therapy Catapult Recent Developments
Table 123. Biovian Corporation Information
Table 124. Biovian Description and Business Overview
Table 125. Biovian Viral Vectors and Plasmid DNA Manufacturing Product
Table 126. Biovian Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 127. Biovian Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 128. Biovian Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 129. Biovian Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 130. Biovian Recent Developments
Table 131. Thermo Fisher Scientific (Brammer Bio) Corporation Information
Table 132. Thermo Fisher Scientific (Brammer Bio) Description and Business Overview
Table 133. Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Product
Table 134. Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 135. Thermo Fisher Scientific (Brammer Bio) Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 136. Thermo Fisher Scientific (Brammer Bio) Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 137. Thermo Fisher Scientific (Brammer Bio) Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 138. Thermo Fisher Scientific (Brammer Bio) Recent Developments
Table 139. VGXI Corporation Information
Table 140. VGXI Description and Business Overview
Table 141. VGXI Viral Vectors and Plasmid DNA Manufacturing Product
Table 142. VGXI Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. VGXI Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 144. VGXI Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 145. VGXI Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 146. VGXI Recent Developments
Table 147. PlasmidFactory Corporation Information
Table 148. PlasmidFactory Description and Business Overview
Table 149. PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Product
Table 150. PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 151. PlasmidFactory Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Product in 2024
Table 152. PlasmidFactory Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Application in 2024
Table 153. PlasmidFactory Revenue Proportion of Viral Vectors and Plasmid DNA Manufacturing by Geographic Area in 2024
Table 154. PlasmidFactory Recent Developments
Table 155. North America Viral Vectors and Plasmid DNA Manufacturing Revenue by Country (2020-2025) & (US$ Million)
Table 156. North America Viral Vectors and Plasmid DNA Manufacturing Revenue by Country (2026-2031) & (US$ Million)
Table 157. North America Viral Vectors and Plasmid DNA Manufacturing Revenue by Type (2020-2025) & (US$ Million)
Table 158. North America Viral Vectors and Plasmid DNA Manufacturing Revenue by Application (2020-2025) & (US$ Million)
Table 159. Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Revenue by Region (2020-2025) & (US$ Million)
Table 160. Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Revenue by Region (2026-2031) & (US$ Million)
Table 161. Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Revenue by Type (2020-2025) & (US$ Million)
Table 162. Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Revenue by Application (2020-2025) & (US$ Million)
Table 163. Europe Viral Vectors and Plasmid DNA Manufacturing Revenue by Country (2020-2025) & (US$ Million)
Table 164. Europe Viral Vectors and Plasmid DNA Manufacturing Revenue by Country (2026-2031) & (US$ Million)
Table 165. Europe Viral Vectors and Plasmid DNA Manufacturing Revenue by Type (2020-2025) & (US$ Million)
Table 166. Europe Viral Vectors and Plasmid DNA Manufacturing Revenue by Application (2020-2025) & (US$ Million)
Table 167. Latin America Viral Vectors and Plasmid DNA Manufacturing Revenue by Country (2020-2025) & (US$ Million)
Table 168. Latin America Viral Vectors and Plasmid DNA Manufacturing Revenue by Country (2026-2031) & (US$ Million)
Table 169. Latin America Viral Vectors and Plasmid DNA Manufacturing Revenue by Type (2020-2025) & (US$ Million)
Table 170. Latin America Viral Vectors and Plasmid DNA Manufacturing Revenue by Application (2020-2025) & (US$ Million)
Table 171. Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Revenue by Country (2020-2025) & (US$ Million)
Table 172. Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Revenue by Country (2026-2031) & (US$ Million)
Table 173. Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Revenue by Type (2020-2025) & (US$ Million)
Table 174. Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Revenue by Application (2020-2025) & (US$ Million)
Table 175. Viral Vectors and Plasmid DNA Manufacturing Key Raw Materials, Industry Status and Trend
Table 176. Viral Vectors and Plasmid DNA Manufacturing Key Raw Materials and Upstream Suppliers
Table 177. Viral Vectors and Plasmid DNA Manufacturing Clients Status and Trend
Table 178. Viral Vectors and Plasmid DNA Manufacturing Typical Clients
Table 179. Viral Vectors and Plasmid DNA Manufacturing Distributors
Table 180. Viral Vectors and Plasmid DNA Manufacturing Market Trends
Table 181. Viral Vectors and Plasmid DNA Manufacturing Market Drivers
Table 182. Viral Vectors and Plasmid DNA Manufacturing Market Challenges
Table 183. Viral Vectors and Plasmid DNA Manufacturing Market Restraints
Table 184. Research Programs/Design for This Report
Table 185. Key Data Information from Secondary Sources
Table 186. Key Data Information from Primary Sources
List of Figures
Figure 1. Viral Vectors and Plasmid DNA Manufacturing Product Picture
Figure 2. Global Viral Vectors and Plasmid DNA Manufacturing Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Type in 2024 & 2031
Figure 4. Plasmid DNA Product Picture
Figure 5. Viral Vectors Product Picture
Figure 6. Global Viral Vectors and Plasmid DNA Manufacturing Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 7. Global Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Application in 2024 & 2031
Figure 8. Cancers
Figure 9. Inherited Disorders
Figure 10. Viral Infections
Figure 11. Others
Figure 12. Viral Vectors and Plasmid DNA Manufacturing Report Years Considered
Figure 13. Global Viral Vectors and Plasmid DNA Manufacturing Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Viral Vectors and Plasmid DNA Manufacturing Market Size (2020-2031) & (US$ Million)
Figure 15. Global Viral Vectors and Plasmid DNA Manufacturing Market Size Market Share by Region: 2024 Versus 2031
Figure 16. Global Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Region (2020-2031)
Figure 17. Global Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share Forecast by Type (2020-2031)
Figure 18. Global Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share Forecast by Application (2020-2031)
Figure 19. Plasmid DNA of Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Application, 2024 VS 2031
Figure 20. Viral Vectors of Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Application, 2024 VS 2031
Figure 21. Viral Vectors and Plasmid DNA Manufacturing Revenue Share by Company (2024)
Figure 22. Viral Vectors and Plasmid DNA Manufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Plasmid DNA Revenue Proportion by Company in 2024
Figure 24. Viral Vectors Revenue Proportion by Company in 2024
Figure 25. North America Viral Vectors and Plasmid DNA Manufacturing Revenue 2020-2031 (US$ Million)
Figure 26. North America Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Type (2020-2025)
Figure 27. North America Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Application (2020-2025)
Figure 28. Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Revenue 2020-2031 (US$ Million)
Figure 29. Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Region (2020-2031)
Figure 30. Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Type (2020-2025)
Figure 31. Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Application (2020-2025)
Figure 32. Europe Viral Vectors and Plasmid DNA Manufacturing Revenue Growth Rate 2020-2031 (US$ Million)
Figure 33. Europe Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Country (2020-2031)
Figure 34. Europe Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Type (2020-2025)
Figure 35. Europe Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Application (2020-2025)
Figure 36. Latin America Viral Vectors and Plasmid DNA Manufacturing Revenue Growth Rate 2020-2031 (US$ Million)
Figure 37. Latin America Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Country (2020-2031)
Figure 38. Latin America Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Type (2020-2025)
Figure 39. Latin America Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Application (2020-2025)
Figure 40. Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Revenue Growth Rate 2020-2031 (US$ Million)
Figure 41. Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Country (2020-2031)
Figure 42. Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Type (2020-2025)
Figure 43. Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Application (2020-2025)
Figure 44. Viral Vectors and Plasmid DNA Manufacturing Supply Chain (Upstream and Downstream Market)
Figure 45. Global Production Market Share of Viral Vectors and Plasmid DNA Manufacturing Raw Materials by Region in 2024
Figure 46. Viral Vectors and Plasmid DNA Manufacturing Distribution Channels
Figure 47. Global Viral Vectors and Plasmid DNA Manufacturing Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 48. Global Viral Vectors and Plasmid DNA Manufacturing Percentage 2020-2031: Online Sales VS Offline Sales
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed
